People who live with both atrial fibrillation and Alzheimer's disease face intertwined risks: the heart rhythm disorder promotes small strokes and silent brain injury that can accelerate cognitive deterioration. A nationwide Swedish observational study in the European Heart Journal, drawing on SveDem, the national registry for cognitive and dementia disorders, suggests the choice of blood thinner may matter for the brain as well as the heart.
The study, with Nanbo Zhu as first author and Maria Eriksdotter as senior author, included 7,308 eligible individuals: 3,341 who used no anticoagulant, 2,277 on warfarin and 1,690 on modern non-vitamin-K oral anticoagulants, known as NOACs. Tracking cognition with the Mini-Mental State Examination, the researchers found NOAC users declined more slowly than warfarin users by 0.21 points per year, and more slowly than non-users by 0.23 points per year.
The authors are deliberately cautious. A difference of roughly 0.2 points a year is small at the individual level, and an observational design cannot prove the drugs protect cognition; they stress the findings are not a reason to prescribe NOACs as a treatment for cognitive decline, and that randomised studies are needed. Still, in a disease with few modifiable levers, even modest pharmacological signals merit serious follow-up.